Beta Bionics Inc (Symbol: BBNX) shares traded at $31.34, exceeding the average analyst 12-month target price of $31.30. This trading occurred recently and raises questions about potential analyst reactions, such as downgrading valuation or adjusting targets higher, depending on the company’s business developments.
Among 10 different analyst targets, estimates range from a low of $23.00 to a high of $35.00, with a standard deviation of $3.334. Currently, there are 9 strong buy ratings and 2 hold ratings, with an average rating of 1.36, where 1 signifies a strong buy and 5 a strong sell.
